Objective: To examine clinical and economic outcomes associated with angiotensin II
receptor blockers (ARB). Methods: Retrospective claims data were analyzed for …

Background Angiotensin-Converting-Enzyme inhibitors (ACE-Is) and Angiotensin Receptors
Blockers (ARBs) reduce the risk of cardiovascular (CV) events in patients with left ventricular …

Background The realization that angiotensin-converting enzyme (ACE) inhibitors do not
provide complete blockade of angiotensin II synthesis has resulted in an increased use of …

Angiotensin-converting enzyme inhibitors (ACEIs) are considered primary drugs for the
secondary prevention of myocardial infarction (MI), and angiotensin receptor blockers …

Angiotensin-converting enzyme (ACE) inhibitors and angiotensin receptor blockers (ARBs)
play a role in the treatment of hypertension (HTN) and heart failure (HF). The literature …

Clinical trials have proved that blockade of the renin‐angiotensin‐aldosterone system
(RAAS) offers primary and secondary protection of the cardiovascular system, brain, and …

Purpose: This article seeks to objectively review the clinical trial evidence to determine
whether angiotensin-converting enzyme inhibitors (ACEIs) and angiotensin-receptor …

Cardiovascular disease represents a continuum that starts with risk factors, such as
hypertension, and progresses to atherosclerosis, target organ damage, and ultimately leads …

Background There are few reviews comparing the long-term outcomes of the use of
angiotensin-converting enzyme inhibitors or angiotensin II receptor blockers in a …

The renin angiotensin aldosterone system (RAAS) plays a central role in the
pathophysiology of hypertension and vascular disease. Angiotensin converting enzyme …